TH75868A - Antibody - Google Patents

Abstract

DC60 (02/08/48) Polypeptides or protein complexes with light chain derivative compounds. Or the weight of the antibodies that are attached to P-selectin glycoprotein ligand-1 Also disclosed are nucleic acids encoded polypeptides, vectors and host cells containing nucleic acids, and a method for inducing activated T-cell death. And modulation of the immune response mediated by intra-animal T cells, polypeptides or protein complexes with light-chain reconstituted compounds. Or the weight of the antibodies that are attached to P-selectin glycoprotein ligand-1 Also disclosed are nucleic acids encoded polypeptides, vectors and host cells containing nucleic acids, and a method for inducing activated T-cell death. And modulation of the immune response mediated by T cells within laboratory animals.

Claims (1)

-18, in order 1., 20, 21, 22, 23, 24, 25 or 26; 3. an isolated nucleic acid comprising the sequence encoding the polypeptide according to claim 1; 4. a vector comprising the nucleic acid according to claim 3; 5. a host cell comprising the nucleic acid according to claim 3; 6. a host cell according to claim 5, wherein the cell is a bacterial cell, a yeast cell, a plant cell, an insect cell or a mammalian cell; 7. a method for making a polypeptide comprising culturing the host cells according to claim 5 in a medium under conditions permitting expression of the polypeptide encoded by the nucleic acid, and purifying the polypeptide from the cultured cells. or cell food 1. -18, respectively. 1. 1 0. The protein complex of claim 8, wherein the protein complex specifically binds to the human P-selectin glycoprotein ligand 1 1 1. The protein complex of claim 10, while binding to the P-selectin glycoprotein ligand 1 on the activated T-cell, induces death of the activated T-cell 1 2. The protein complex of claim 8, wherein the second polypeptide comprises a constant region of the immunoglobulin heavy chain. (immunoglobulin heavy chain constant region) 1 3. The protein complex of claim 12, wherein the protein complex is the antibody 1 4. The protein complex of claim 13, wherein the antibody is a monoclonal, chimeric or humanized antibody 1 5. The protein complex which specifically binds to human P-selectin glycoprotein ligand 1 without interfering with the binding between P-selectin glycoprotein ligand 1 and P-selectin, wherein the protein complex upon binding to P-selectin glycoprotein ligand 1 on activated T cells induces death of the activated T cells 1 1. 6 respectively 1 1. respectively 1 8. The protein complex of claim 15, wherein the second polypeptide comprises: The protein complex of claim 18, wherein the protein complex is the antibody 2 0. The protein complex of claim 19, wherein the antibody is a monoclonal, chimeric or humanized antibody 2 1. The protein complex which specifically binds to amino acid residues 115-126 of human P-selectin glycoprotein ligand 1 2 2. The protein complex of claim 21, wherein the protein complex, upon binding to P-selectin glycoprotein ligand 1 on activated T cells, includes apoptosis of the activated T cells 2 1. 6 respectively 2 1. 2 5. The protein complex of claim 21, wherein the second polypeptide comprises: Immunoglobulin heavy chain stable region 2 6. The protein complex of claim 25, wherein the protein complex is the antibody 2 7. The protein complex of claim 26, wherein the antibody is a monoclonal, chimeric or humanized antibody 2 2 8. A method for inducing apoptosis of activated T cells comprising contacting the protein complex of claims 8, 15 or 21 with the activated T cells, wherein binding of the protein complex to the activated T cells induces apoptosis of the activated T cells 2 9. A method for modulating the immune response mediated by T cells in an experimental animal, comprising: determining whether the experimental animal has or is at risk of developing a condition characterized by an immune response mediated by excess T cells; and using the protein complex of claims 8, 15 or 21 In an amount that is effective in 3 test animals. The method according to claim 29, wherein the condition is an inflammatory disease, autoimmune disease, allergic disease, or T-cell cancer. 1. A method according to claim 29, wherein the experimental animal receives, or is deemed to receive, allogeneic or xenogeneic transplantable tissue.